多发性骨髓瘤患者骨髓Flk1^+间充质干细胞的成骨能力降低  

Decreased osteogenic potential of marrowFlk1^+ mesenchymal stem cells of multiple myeloma patients

作　　者：李炳宗[1] 李静[1] 史明霞[1] 陈磊[2] 高伟波[1] 赵春华[1] 

机构地区：[1]中国医学科学院中国协和医科大学基础医学研究所组织工程研究中心,北京100005 [2]中国医学科学院中国协和医科大学血液病研究所血液病医院实验血液学国家重点实验室,天津300020

出　　处：《基础医学与临床》2006年第6期586-592,共7页Basic and Clinical Medicine

基　　金：国家高技术研究发展计划项目(2002AA205061)

摘　　要：目的研究多发性骨髓瘤(MM)患者骨髓F lk1+间充质干细胞(F lk1+MSCs)的成骨特性,探讨其与多发性骨髓瘤骨病的关系。方法分离并鉴定MM患者骨髓源F lk1+MSCs;利用实时定量RT-PCR检测F lk1+MSCs成骨诱导前后成骨指标的表达,诱导2周后用Von-Kossa染色法测定钙盐沉积;同时测定F lk1+MSCs中转录共刺激因子(TAZ)的表达。结果MM患者骨髓F lk1+MSCs在体外经成骨诱导后,其成骨指标的表达较正常人明显降低,Von-Kossa染色也可见矿化基质沉积相应减低。同时F lk1+MSCs中TAZ的表达在MM中较正常人明显下调(P<0.05)。结论多发性骨髓瘤患者的骨髓F lk1+MSCs成骨能力较正常人减低,此因素可能参与了MM患者骨病的发病环节,而TAZ表达的减弱可能在此过程中发挥一定作用。Objective To detect the osteogenic characteristic of marrow Flk1^＋ mesenchymal stem cells （Flk1^＋ MSCs） of multiple myeloma （MM） patients, and to investigate its relationship with MM. Methods Real-time RTPCR was employed to test osteogenic markers and a 14-3-3 - binding protein, TAZ （ transcriptranscriptional coactivator with PDZ-binding motif） expressions of Flk1^＋ MSCs of MM before and after osteogenic differentiation, and von Kossa staining was performed to evaluate the mineral deposition after osteogenic differentiation. Results Osteogenie markers and TAZ expressions in Flk1^＋ MSCs of MM decreased significantly as compared to healthy donors, and mineral deposition was decreased in MM group （ P 〈 0. 05 ）. Conclusion Osteogenic potential of marrow Flk1^＋ MSCs of myeloma patients is decreased and the abnormal TAZ expression may play a role in this pathology process.

关 键 词：多发性骨髓瘤 间充质干细胞 成骨 转录共刺激因子 

分 类 号：R733.3[医药卫生—肿瘤]